0001104659-25-059295.txt : 20250613 0001104659-25-059295.hdr.sgml : 20250613 20250613145040 ACCESSION NUMBER: 0001104659-25-059295 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-87570 FILM NUMBER: 251045875 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A BUSINESS ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 SCHEDULE 13G/A 1 primary_doc.xml SCHEDULE 13G/A 0001193125-14-339137 0000924223 XXXXXXXX LIVE 12 Common Stock 06/01/2025 0001439222 Agios Pharmaceuticals, Inc. 00847X104 88 Sidney Street Cambridge MA 02139 Rule 13d-1(c) BB Biotech AG a V8 0.00 0.00 0.00 0.00 0.00 N 0 HC CO This Amendment No. 12 constitutes an exit filing for the Reporting Person as the Reporting Person owns less than five percent (5%) of the common shares of the Issuer. Biotech Target N.V. a P8 0.00 0.00 0.00 0.00 0.00 N 0 CO This Amendment No. 12 constitutes an exit filing for the Reporting Person as the Reporting Person owns less than five percent (5%) of the common shares of the Issuer. Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA, 02139 BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target") BB Biotech: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland Biotech Target: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curacao BB Biotech: Switzerland Biotech Target: Curacao Y 0 0% 0 0 0 0 N Y Y N This statement is filed jointly by BB Biotech and Biotech Target. Biotech Target is a wholly-owned subsidiary of BB Biotech. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.* * Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on September 11, 2014. BB Biotech AG /s/ Christian Koch 06/13/2025 /s/ Ivo Betschart 06/13/2025 Biotech Target N.V. /s/ Jan Bootsma 06/13/2025 /s/ Hugo von Neutegem 06/13/2025